Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.73 |
| ▸ | MMP12 | P39900 | 1/20 | 0.73 |
| ▸ | NR1I2 | O75469 | 7/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3092955 | 0.92 | PRKCA (0.76) | PRKCAMMP12NR1I2CYP3A4CYP2C9 | |
| Mk-3281 SCHEMBL3092945 | 0.89 | PRKCA (0.92) | PRKCAMMP12NR1I2CYP3A4CYP2C9 | |
| Mk-3281 SCHEMBL3085872 | 0.89 | PRKCA (0.92) | PRKCAMMP12NR1I2CYP3A4CYP2C9 | |
| Mk-3281 SCHEMBL3086966 | 0.89 | PRKCA (0.92) | PRKCAMMP12NR1I2CYP3A4CYP2C9 | |
| SCHEMBL3092202 | 0.89 | PRKCA (0.67) | PRKCAMMP12NR1I2CYP3A4CYP2C9 | |
| SCHEMBL3088796 | 0.88 | PRKCA (0.64) | PRKCAMMP12NR1I2CYP3A4CYP2C9 | |
| Trifluoroacetic Acid SCHEMBL3093777 | 0.88 | PRKCA (0.72) | PRKCAMMP12NR1I2CYP3A4CYP2C9 | |
| Trifluoroacetic Acid SCHEMBL3092631 | 0.88 | PRKCA (0.72) | PRKCAMMP12NR1I2CYP3A4CYP2C9 | |
| SCHEMBL3089838 | 0.87 | PRKCA (0.63) | PRKCAMMP12NR1I2CYP3A4KCNH2 | |
| SCHEMBL3086590 | 0.87 | PRKCA (0.64) | PRKCAMMP12NR1I2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795247-B2 | Tetracyclic indole derivatives as antiviral agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2010-09-14 | — | — | US | claimed |
| US-20220356182-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2022-11-10 | — | — | US | disclosed |
| EP-2953461-B1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C | MERCK SHARP & DOHME (US) | 2020-04-22 | — | — | EP | disclosed |
| EP-2953462-B1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C | MERCK SHARP & DOHME (US) | 2020-04-08 | — | — | EP | disclosed |
| EP-2780026-B1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-23 | — | — | EP | disclosed |
| EP-2953456-B1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C | MERCK SHARP & DOHME (US) | 2019-05-22 | — | — | EP | disclosed |
| US-20190127365-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2019-05-02 | — | — | US | disclosed |
| EP-2086982-B1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-08-29 | — | — | EP | disclosed |
| US-9738661-B2 | HCV NS3 protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9493461-B2 | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis C | MERCK SHARP & DOHME CORP. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20100093779-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-04-15 | — | — | US | disclosed |
| EP-1924593-B9 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO INC (US) | 2010-02-17 | — | — | EP | disclosed |
| US-20100035835-A1 | NUCLEOSIDE ARYL PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION | MERCK SHARP & DOHME LLC | 2010-02-11 | — | — | US | disclosed |
| US-20100029666-A1 | Macrocyclic Quinoxaline Compounds as HCV NS3 Protease Inhibitors | MERCK SHARP & DOHME LLC | 2010-02-04 | — | — | US | disclosed |
| US-7632821-B2 | Ribonucleoside cyclic acetal derivatives for the treatment of RNA-dependent RNA viral infection | MERCK & CO., INC. (US) | 2009-12-15 | — | — | US | disclosed |
| EP-1924593-B1 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO INC (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20090124661-A1 | HCV NS3 PROTEASE INHIBITORS | MERCK & CO., INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090118223-A1 | Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives | MERCK SHARP & DOHME CORP. | 2009-05-07 | — | — | US | disclosed |
| US-20090099126-A1 | Ribonucleoside Cyclic Acetal Derivatives for the Treatment of RNA-Dependent RNA Viral Infection | MERCK SHARP & DOHME CORP. | 2009-04-16 | — | — | US | disclosed |
| US-20060100262-A1 | Tetracyclic indole derivatives as antiviral agents | ISTITUTO DI RICHERCHEDI BIOLOGIA MOLECOLARE P ANGELETTI SPA (IRMB) (IT) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124661-A1 | HCV NS3 PROTEASE INHIBITORS | HAVCR2, GTF3C3, CTSC | PRKCA 2980/4885MMP12 773/4885NR1I2 613/4885 |
| US-20060100262-A1 | Tetracyclic indole derivatives as antiviral agents | IDO1, ZC3HAV1, IDO2 | PRKCA 3874/4885MMP12 3319/4885NR1I2 144/4885 |
| US-20090099126-A1 | Ribonucleoside Cyclic Acetal Derivatives for the Treatment of RNA-Dependent RNA Viral Infection | RNASE1, RNASEL, NSUN2 | PRKCA 2558/4885MMP12 2776/4885NR1I2 755/4885 |
| US-20190127365-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | PRKCA 1517/4885MMP12 3182/4885NR1I2 643/4885 |
| US-20220356182-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | PRKCA 1517/4885MMP12 3182/4885NR1I2 643/4885 |
| US-20100093779-A1 | HCV NS3 PROTEASE INHIBITORS | HAVCR2, GTF3C3, CTSC | PRKCA 2980/4885MMP12 773/4885NR1I2 613/4885 |
| US-20090118223-A1 | Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives | MTAP, NT5C3B, NSUN2 | PRKCA 559/4885MMP12 3480/4885NR1I2 1191/4885 |
| US-20100035835-A1 | NUCLEOSIDE ARYL PHOSPHORAMIDATES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRAL INFECTION | NSUN2, NSUN3, RNGTT | PRKCA 3283/4885MMP12 3965/4885NR1I2 1112/4885 |
| US-20100029666-A1 | Macrocyclic Quinoxaline Compounds as HCV NS3 Protease Inhibitors | KEAP1, CTSC, SPINT2 | PRKCA 3996/4885MMP12 1075/4885NR1I2 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.